Cytokine inhibitors for sepsis and septic shock

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 1, 2001, Pages 24-29

  Orlicek, Shari L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; CYTOKINE INHIBITOR; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; META ANALYSIS; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 0035132604     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.19232     Document Type: Article

References (48)

1. Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia
2. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer
3. Activation of coagulation after administration of tumor necrosis factor to normal subjects
4. Effects of leukocytes following injection of tumor necrosis factor into healthy humans
5. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock
6. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever
7. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans
8. The toxic and hematologic effects of interleukin-1 alpha administered in a phase 1 trial to patients with advanced malignancies
9. A phase 1 trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer
10. Interleukin-1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition
11. Role of interleukin-1 and tumor necrosis factor on energy metabolism in rabbits
12. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
13. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
14. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock
15. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice: Comparative protective efficacy of antibodies to tumor necrosis factor and to lipopolysaccharide
16. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia
17. Lethal S aureus shock in primates: Prevention of death with anti-TNF antibody
18. Observations on the role of tumor necrosis factor-α in a murine model of shock due to Streptococcus pyogenes
19. Monoclonal antibody to TNF in severe septic shock
20. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
21. Administration of anti-TNF antibody improves left ventricular function in septic shock patients: Results of a pilot study
22. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome
23. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis
24. Double blind, randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock
25. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia
26. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis
27. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: Comparison with anti-TNF monoclonal antibody
28. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD 120a)-Ig fusion protein, Ro 45-2081
29. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
30. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
31. Impact of immunomodulating therapy on mortality in patients with severe sepsis
32. Modalities for reducing interleukin-1 activity in disease
33. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist
34. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction
35. Primary structure and functional expression from complimentary DNA of a human IL-1 receptor antagonist
36. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock
37. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice
38. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial
39. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized double-blind, placebo-controlled trial
40. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
41. Interleukin-1 receptor antibody (IL-1rab) protection and treatment against lethal endotoxemia in mice
42. Oxpentifylline in endotoxaemia
43. Effect of amrinone on tumor necrosis factor production in endotoxic shock
44. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzecs
45. Pentoxifylline treatment of sepsis in conscious Yucatan minipigs
46. Influence of pcntoxifylline on cytokine levels and inflammatory parameters in septic shock
47. Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study
48. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial